Chemosensitivity linked to p73 function

Cancer Cell

Volumn 3, Issue 4, 2003, Pages 403-410

  Irwin, Meredith S ^a,c   Kondo, Keiichi ^a   Marin, Maria Carmen ^a   Cheng, Lynn S ^c   Hahn, William C ^a   Kaelin Jr , William G ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MUTANT PROTEIN; PROTEIN P73; RNA; DNA BINDING PROTEIN; NUCLEAR PROTEIN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ANIMAL CELL; ARTICLE; BIOENGINEERING; CELL TRANSFORMATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; SEQUENCE HOMOLOGY; TUMOR CELL; ANIMAL; APOPTOSIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FIBROBLAST; GENETICS; METABOLISM; MUTATION; NICK END LABELING; PHYSIOLOGY; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; EMBRYO; FIBROBLASTS; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; IN SITU NICK-END LABELING; MICE; MUTATION; NUCLEAR PROTEINS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0041997348     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00078-3     Document Type: Article

References (42)

1. Agami R., Blandino G., Oren M., Shaul Y. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature. 399:1999;809-813.
2. Bensaad K., Le Bras M., Unsal K., Strano S., Blandino G., Tominaga O., Rouillard D., Soussi T. Change of conformation of the DNA binding domain of p53 is the only key element for binding of and interference with p73. J. Biol. Chem. 278:2003;10546-10555.
3. Bergamaschi D., Gasco M., Sullivan A.S., Yulug I., Reelfs O., Trigiante G., Farrell P.J., Lu X., Crook T. p53 polymorphism modulates chemosensitivity in vitro and in vivo via p73. Cancer Cell. 3:2003;387-402.
4. Blandino G., Levine A., Oren M. Mutant p53 gain of function. differential effects of different p53 mutants on resistance of cultured cells to chemotherapy Oncogene. 18:1999;477-485.
5. Brooks L.A., Tidy J.A., Gusterson B., Hiller L., O'Nions J., Gasco M., Marin M.C., Farrell P.J., Kaelin W.G. Jr., Crook T. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res. 60:2000;6875-6877.
6. Brown J.M., Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1999;1391-1399.
7. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8:2002;282-288.
8. Cai Y.C., Yang G., Nie Y., Wang L.D., Zhao X., Song Y., Seril D.N., Liao J., Xing E.P., Yang C.S. Molecular alterations of p73 in human esophageal squamous cell carcinomas. loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53 Carcinogenesis. 21:2000;683-689.
9. Chen X., Zheng Y., Zhu J., Jiang J., Wang J. p73 is transcriptionally regulated by DNA damage, p53, and p73. Oncogene. 20:2001;769-774.
10. Costanzo A., Merlo P., Pediconi N., Fulco M., Sartorelli V., Cole P.A., Fontemaggi G., Fanciulli M., Schiltz L., Blandino G.et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell. 9:2002;175-186.
11. Di Como C.J., Gaiddon C., Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19:1999;1438-1449.
12. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498.
13. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 416:2002;560-564.
14. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 286:1999;2507-2510.
15. Gaiddon C., Lokshin M., Ahn J., Zhang T., Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21:2001;1874-1887.
16. Gong J., Costanzo A., Yang H.Q., Melino G., Kaelin W.G., Levero M., Wang J. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 399:1999;806-808.
17. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.
18. Harlow E., Crawford L.V., Pim D.C., Williamson N.M. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39:1981;861-869.
19. Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V. Molecular basis For heterogeneity of the human p53 protein. Mol. Cell. Biol. 6:1986;4650-4656.
20. International Agency for Research on Cancer TP53 Mutation Database ( http://www.iarc.fr/p53/ ).
21. Irwin M.S., Kaelin W.G. p53 family update. p73 and p63 develop their own identities Cell Growth Differ. 12:2001;337-349.
22. Irwin M., Marin M.C., Phillips A.C., Seelan R.S., Smith D.I., Liu W., Flores E.R., Tsai K.Y., Jacks T., Vousden K.H., Kaelin W.G. Jr. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 407:2000;645-648.
23. Ishimoto O., Kawahara C., Enjo K., Obinata M., Nukiwa T., Ikawa S. Possible oncogenic potential of DeltaNp73. a newly identified isoform of human p73 Cancer Res. 62:2002;636-641.
24. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis. a link between cancer genetics and chemotherapy Cell. 108:2002;153-164.
25. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.-C., Valent A., Minty A., Chalon P., Lelias J.-M., Dumont X.et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:1997;809-819.
26. Ko L.J., Prives C. p53. puzzle and paradigm Genes Dev. 10:1996;1054-1072.
27. Li R., Sutphin P., Schwartz D., Matas D., Almog N., Wolkowicz R., Goldfinger N., Pei H., Prokocimer M., Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene. 16:1998;3269-3277.
28. Mai M., Yokomizo A., Qian C., Yang P., Tindall D.J., Smith D.I., Liu W. Activation of p73 silent allele in lung cancer. Cancer Res. 58:1998;2347-2349.
29. Marin M.C., Jost C.A., Brooks L.A., Irwin M.S., O'Nions J., Tidy J.A., James N., McGregor J.M., Harwood C.A., Yulug I.G.et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25:2000;47-54.
30. McCaffrey A.P., Meuse L., Pham T.T., Conklin D.S., Hannon G.J., Kay M.A. RNA interference in adult mice. Nature. 418:2002;38-39.
31. Melino G., De Laurenzi V., Vousden K.H. p73. Friend or foe in tumorigenesis Nat. Rev. Cancer. 2:2002;605-615.
32. Pozniak C.D., Radinovic S., Yang A., McKeon F., Kaplan D.R., Miller F.D. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science. 289:2000;304-306.
33. Rodrigues N.P., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.R., Gannon J.V., Lane D.P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA. 87:1990;7555-7559.
34. Soulitzis N., Sourvinos G., Dokianakis D.N., Spandidos D.A. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 179:2002;175-183.
35. Stiewe T., Putzer B.M. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat. Genet. 26:2000;464-469.
36. Stiewe T., Theseling C.C., Putzer B.M. Transactivation-deficient delta TA-p73 inhibits p53 by direct competition for DNA binding. Implications for tumorigenesis. J. Biol. Chem. 277:2002;14177-14185.
37. Vossio S., Palescandolo E., Pediconi N., Moretti F., Balsano C., Levrero M., Costanzo A. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene. 21:2002;3796-3803.
38. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A.et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 404:2000;99-103.
39. Yuan Z.-M., Shioya H., Ishiko T., Sun X., Gu J., Huang Y., Lu H., Kharbanda S., Weichselbaum R., Kufe D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic reponse to DNA damage. Nature. 399:1999;814-817.
40. Zaika A.I., Kovalev S., Marchenko N.D., Moll U.M. Overexpression of the wild-type p73 gene in breast cancer tissues and cell lines. Cancer Res. 59:1999;3257-3263.
41. Zaika A., Irwin M., Sansome C., Moll U.M. Oncogenes induce and activate endogenous p73 protein. J. Biol. Chem. 276:2001;11310-11316.
42. Zaika A.I., Slade N., Erster S.H., Sansome C., Joseph T.W., Pearl M., Chalas E., Moll U.M. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196:2002;765-780.